Who is Eric Lefkofsky and what is Tempus? Lefkofsky is the Co-Founder of Groupon, along with several other businesses, including Tempus. Tempus is a cutting edge technology company that gathers data in order to improve cancer care. The company is now receiving funding in order to continue down the path of cancer research and care for individuals. Lefkofsky continues to spearhead the use of technology in order to benefit patients.
Tempus has recently received 80 million dollars in funding from groups of new and existing investors. With this new funding, they are able to continue to grow the company. At already 400 employees, they need the funding in order to add more workforce to drive their mission. Success is something that Eric Lefkofsky is used to seeing as co-founder of several innovative companies. He wants to use the newest technology in order to continue the best care for cancer patients across the United States.
Tempus likes to focus on improving care. They gather data based on treatment that was provided to previous patients, then use that to evaluate the best goals. The leadership team works together in order to personalize care by collecting large volumes of information, to find what will provide the most advantages. As a team they are excited to see technology continue to help patients during their most vulnerable time.
As part of the Lefkofsky Family Foundation, the private charitable foundation aims to fund medical research. The foundation, Co-Chaired by Eric Lefkofsky, along with his wife, focuses on providing care to those who are in need, with a focus on acute cancer research. Having a history of Cancer in their family has propelled them to both look for ways to cure cancer, and increase quality of life.
If Lefkofsky can continue to empower doctors to find ways to evaluate cancer for the benefits of patients, then he is meeting his lifelong goals within his company. He continues to strive for efforts in doing so, and promoting that Tempus will be the company to promote better healthcare for citizens.
The people behind Oncotarget has an advocacy to increase public awareness on the work that is being done by so many excellent oncologists around the world. They believe that as more and more people know about the progress of cancer treatment and the many types of it, it increases the value of the work done by their fellow oncologists and therefore making their work more efficient.
In the fight against one of the most fatal diseases on earth, increasing public awareness is essential especially as for most people; they only know that cancer treatment is expensive. But every week, oncologists are making progress in making cancer treatment more available and affordable for everyone, and this is what Oncotarget wants to highlight. Learn more about Oncotarget at researchgate.net
Oncotarget is an online journal which is open access to everyone. It is peer-reviewed by fellow oncologists, and per week, they release two issues. The editors-in-chiefs of Oncotarget themselves are both renowned Oncologists that have done much in the fight against cancer. They are Andrei V. Gudkov and Mikhail Blagosklonny. Mikhail is known for his work with the wonder drug ‘Rapamycin,’ and Andrei is known for his research on DNA repair. They feel that it is also their duty to highlight the clinical studies, publications, and trials made by their peers because they know there are many great oncologists out there whose work deserves to be highlighted to the public. Oncotarget is so serious about this advocacy that they even created a podcast which is available on iTunes, Stitcher, and Player.FM
Because of how the Oncotarget website was made, visitors can check peer-reviewed articles about Oncology and many other subjects, like studies about the process of aging and new treatments for different types of diseases, and these visitors never actually pay for that service. The Oncotarget articles are free to read, copy, paste, and share with your friends or with someone that you think will benefit from knowing about that particular study. Watch this video on Youtube.
The work of Oncotarget has revolutionized the way that the research field in Oncology works, as, now, one of the most visited websites in the field is free to read.
According to a story published by NewsWise, this accolade is considered a higher education gold standard and the tribute illustrates commitment to an academic discipline, guaranteeing continued progression and support.
These chairs – part of the Rutgers University’s “18 Chair Challenge” – were established to recognize $1.5 million donations to match each of 18 new chairs that would result in $3 million endowments in the fields of genomic science and precision medicine.
Precision medicine and genomic science is revolutionizing how the medical community is treating cancer diagnosis and treatment. The procedures involve analyzing tumors and tackling them on the genetic level. This allows oncologists to tailor specialized therapies. Rutgers Cancer Institute is one of the country’s first facilities to apply genomic sequencing to precision medicine. It has been instrumental in developing innovative therapies for rare cancers.
With advancements in precision medicine, there will be a greater utility for classifying cancers and determining better patient outcomes through individualized therapies.
After four decades, Omar Boraie is considered a visionary. His current project is a luxury, residential high rise on Somerset Street in New Brunswick. The 73 year old is founder, patriarch and president of Boraie Development LLC and sees the new project as another component of his dream to rebuild his beloved Jersey city in the same ways he witnessed in Europe as a young man.
Boraie has taken a great interest in the advances of precision medicine at Rutgers Cancer Institute. The developer has a background in chemistry. “Just as the anonymous donor for the ‘18 Chair Challenge’ encouraged others to come forward, I hope my family’s pledge will also inspire others to do the same.”
Boraie has been a consistent presence in the New Brunswick medical community. He was heavily involved in “Healthcare City” and many medical professionals believe his support of genomic science will have a significant influence on cancer patient treatment for generations to come.
The Cancer Institute of New Jersey is a network of hospitals across the state. The Rutgers Cancer Institute is one of the state of New Jersey’s first designated comprehensive cancer centers. They are involved in the most extensive research for treatment, detection and cancer patient care, as well as a primary educational resource for prevention.
Seattle Genetics ranks up as a well-established and successful biotechnology company globally. The company came into inception in 1998 with an objective of creating and commercializing empowered and innovative monoclonal antibody-based therapies that target the treatment of cancer.
Since its inception, it has managed to position itself as a premier developer of antibody-drug conjugates. ADCs utilize a technology that harnesses the potential of monoclonal antibodies in delivering killing agents to cancer cells directly. The ADCs spare non-targeted cells while reducing the numerous toxic effects associated with traditional chemotherapy.
Seattle Genetics prides itself on the success of its ADCETRIS product. ADCETRIS has entered various markets across the globe including the European Union, the United States, Canada and Japan. Currently, the company is making various endeavors of assessing another antibody-drug conjugate technology using pyrrolobenzodiazepine (PMB) dimer, a highly effective cytotoxic agent.
The company boasts of multiple partnerships, which comprise of an agreement with Genentech for SGN-40 priced over $860 million. The multiple agreements also consist of ADC collaborations with other companies such as Medlmmune, Progenics, Bayer and CuraGen. Since 2011, the ADC agreements have generated over b$65 million for Seattle Genetics.
Clay Siegall, popularly known as Dr. Siegall, is acknowledged for co-founding the Seattle Genetics, a premier biotechnology company, in 1998. Apart from being the co-founder of Seattle Genetics, he serves as its Chief Executive Officer, President as well as Chairperson of the Board of Directors. Clay has significantly aided Seattle Genetics in the creation of a diverse pipeline comprising of antibody-based cancer therapies. ADCETRIS (brentuximab vedotin) serves as one of the company’s main therapies, especially after gaining approval from the US Food and Drug Administration in 2011.
Siegall has also proven to be highly qualified in attracting financiers, as he has assisted Seattle Genetics in securing over $675 million via both private and public funding. His academic qualifications is characterized by a B.S degree in Zoology from the popular University of Maryland and a Genetics Ph.D. from the George Washington University. With such an impressive academic record of accomplishment, he has served numerous entities such as the National Institutes of Health, National Cancer Institute, and the Bristol-Myers Squibb Pharmaceutical Research Institute.
Mirna Therapeutics a biotechnology company that specializes in the development of micro-RNA announced in 2013 that Dr. Clay Siegall would be the outside director for the board of directors of Seattle Genetics. Dr. Siegel is also the CEO president and co-founder of the company. My car is a development in the area of cancer research. Dr. Clay Siegel is excited to be a part of the company’s development in micro therapeutic products.
Dr. Siegall co-founded Seattle Genetics in 1998, and they have created many antibody-based therapies to help treat cancer patients. Seattle Genetics has worked together with many world-renowned biomedical and oncology companies to create better strategies, and breakthroughs in the are of cancer research and treatment techniques. His diligent work has helped to develop many alternative treatments for cancer patients that had needs that were not being met through traditional cancer treatment methods. He continues to be on the forefront of research and development in the oncology area.
Dr. Siegall has been involved with many other large corporations in the medical field such as Bristol-Meyers Squib between the years of 1991 until 1997. He worked with the National Institute of Health between 1988 until 1991. He has also collaborated with National Cancer Treatment Centers.
Dr. Seigall is also and inventor and an author. He has authored over 70 publications and held fifteen patents for his inventions. Dr. Clay Siegall earned his bachelor’s in Zoology from the University of Maryland. He received his Ph.D. in the field of Genetics from George Washington University.